– CHINA, Hong Kong – Regencell Bioscience Holdings Limited (NASDAQ: RGC) today announced the appointment of Dr. William Wing-Yan Lo (Ph.D.) to its Board of Directors, effective immediately.
“We are delighted to welcome Dr. Lo to our Board of Directors. His wealth of strategic and leadership skills, academic medicine and business advisory experience makes him an excellent addition to our board. We welcome his insight and wisdom,” said Founder and CEO, Yat-Gai Au.
Dr. Lo will join the audit committee as its chair and the compensation committee and the nomination and corporate governance committee as a member.
About Dr. William Wing-Yan Lo
Dr. Lo brings over three decades of biopharma, academic medicine, corporate governance, and strategic advisory experience. Dr. Lo graduated from Cambridge University with a Master of Philosophy Degree in Pharmacology and a Ph.D. Degree in Molecular Neuroscience. Dr. Lo started his career in McKinsey & Company Inc. as a management consultant and held senior positions in China Unicom, Hongkong Telecom, Citibank HK, I.T Limited, South China Media Group and Kidsland International Holdings Limited in the past.
Dr. Lo currently serves as an independent non-executive director of a number of public companies listed on the Main Board of The Stock Exchange of Hong Kong Limited; Dr. Lo is an independent non-executive director of Television Broadcasts Ltd (HKSE: 511), OCI International Holdings Limited (HKSE: 329), CSI Properties Limited (HKSE: 497), Jingrui Holdings Limited (HKSE: 1862), and Oshidori International Holdings Limited (HKSE: 622). Dr. Lo was also an independent non-executive director of Nam Tai Property Inc. (NYSE: BTP).
Dr. Lo was appointed a Justice of Peace of the Government of the Hong Kong Special Administrative Region and is the founding governor of the Charles K. Kao Foundation for Alzheimer’s Disease and the ISF Academy as well as the present chairman of Junior Achievement HK.
Dr. Lo added, “I am grateful for the opportunity to join Regencell’s Board of Directors, I look forward to working alongside my fellow directors to help guide the Company’s business strategy in developing and bringing to the market TCM treatments for ADHD and ASD disorders and infectious diseases affecting people’s immune system such as COVID.”
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems such as COVID. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID-related treatments to patients in ASEAN countries, India, Japan, Australia, and New Zealand.
For more information : https://www.regencellbioscience.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.